Dr Landgren on the Rationale for Utilizing MRD as a Clinical

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

Related Keywords

Miami , Florida , United States , University Of Miami , Paulj Dimare , C Ola Landgren , , National Cancer Institute , Clinical Oncology Program , Oncologic Drugs Advisory Committee , Sylvester Myeloma Institute , University Of Miami Health System , Sylvester Comprehensive Cancer Center , Department Of Medicine , University Of Miami Miller School Medicine , Division Of Myeloma , Ola Landgren , Mare Endowed Chair , Miami Miller School , Miami Health System , Drugs Advisory Committee ,